Mr. Tolchinsky, a graduate of Cornell University and Tulane Law School, has a strong background in Research and Development, intellectual property protection and regulatory compliance. Mr. Tolchinsky has been employed by the patent department of Webb & Associates in Rechovot, Israel, the R&D department of Mazal Pharmaceuticals, Inc., Hadassah Ein Kerem Hospital, Jerusalem, Israel, R.A.M. Technologies, Jerusalem, Israel, and Halsey Group Consultants in New Jersey.
Mr. Tolchinsky stated, "I am looking forward to bringing the company to the next stage of development."
Mazal's new corporate counsel is Stephen M. Fleming, Law Offices of Stephen M. Fleming PLLC, 110 Wall Street, 11th Floor, New York, New York 10005, Phone 516-833-5034.
About Mazal Plant Pharmaceuticals Inc.
Mazal Plant Pharmaceuticals, Inc. is an early-stage whole plant pharmaceutical development company whose mission is to develop treatments for chronic diseases from combinations of whole plants and to build shareholder value through negotiated relationships with strategic partners to fund commercialization and marketing of these treatments on a stand-alone or combination basis.
Mazal Plant Pharmaceuticals has been approved to conduct a large-scale, double-blind, 4-arm study in human subjects diagnosed with alphalipoproteinemia (subjects with low HDL). The subjects will be given either MAHDL, placebo, Statin + Placebo or MAHDL + Statin for 4 months and tested for changes in HDL, LDL, Cholesterol, Triglycerides and CRP serum levels.
Additional information on Mazal Plant Pharmaceuticals, Inc. may be found at: http://www.mazalpharmaceutical.com.
Forward-Looking Statements
"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of 1995 This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements Mazal Plant Pharmaceuticals Inc., to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Mazal Plant Pharmaceuticals Inc.'s subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Mazal Plant Pharmaceuticals assumes no responsibility to update the information included herein for events occurring after the date hereof.
Contact: LC Group Rick Lutz (404) 261-1196
